Emergers Feed

2025-12-12 08:00:00 Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell

2025-11-14 08:00:00 Equity Research | CRUNCHFISH: Breakthrough integration sets stage for commercial expansion

2025-11-07 08:00:00 Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

2025-09-25 08:00:00 Video | CRUNCHFISH: Lunchsnack om ny finansiering, affärs- och marknadstrategi samt nytt pilotavtal

2025-09-22 11:45:00 Inbjudan till lunchsnack med CRUNCHFISH vd Joachim Samuelsson onsd 24 september kl 12:00-13:00

2025-08-29 08:00:00 Equity Research | PROLIGHT: Financing and partner interest strengthen case ahead of regulatory study

2025-08-28 08:00:00 Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

2025-08-25 15:00:00 Video | CRUNCHFISH: Lunchsnack om halvårsrapporten med VD Joachim Samuelsson

2025-08-25 08:00:00 Equtiy Research | CRUNCHFISH: Improved outlook with NPCI adoption and global validation + Lunchsnack (in SWE)

2025-08-11 16:00:00 Video | CRUNCHFISH: Lunchsnack med vd Joachim Samuelsson om bolagets strategi och marknadsutvecklingen

2025-08-08 10:00:00 Inbjudan till lunchsnack med CRUNCHFISH vd Joachim Samuelsson månd 11 augusti kl 12:00-13:00

2025-07-03 08:00:00 Equity Research | PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships

2025-06-18 08:00:00 Equity Research | PROLIGHT: Positive patient data and patent approval strengthen case for Psyros

2025-06-12 08:00:00 VIDEO: Lunchsnack med CRUNCHFISH vd Joachim Samuelsson om Rethinking Payments

2025-06-10 08:00:00 Välkommen på lunchsnack med CRUNCHFISH vd Joachim Samuelsson onsdag 11 juni kl 12:00-13:00

2025-05-26 08:00:00 Video | CRUNCHFISH: Lunchsnack med vd Joachim Samuelsson om nya approachen till Offline Payments

2025-05-26 08:00:00 Equity Research | CRUNCHFISH: Third time a charm? New offline strategy targets system integration

2025-05-23 08:00:00 Equity Research | Prolight Diagnostics AB: Gearing up for commercialisation with strong insider backing

2025-05-22 10:00:00 Välkommen på lunchsnack med CRUNCHFISH vd Joachim Samuelsson fredag 23 maj kl 12:00-13:00

2025-05-07 08:00:00 Equity Research | NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push

2025-04-17 08:00:00 Video från lunchseminarium med CRUNCHFISH vd Joachim Samuelsson

2025-04-14 08:00:00 Välkommen på lunchseminarium med CRUNCHFISH vd Joachim Samuelsson onsdag 16 april kl 12:00-13:00

2025-04-01 08:00:00 Equity Research | PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation

2025-03-06 09:50:00 Equity Research | TALLINK: Free cash flow support dividends

2025-02-20 08:00:00 Equity Research | Nanexa AB: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end

2025-02-14 08:00:00 Equity Research | Crunchfish: Still in the running for a one billion-user Digital Cash market

2025-01-27 08:00:00 Equity Research | NANEXA: Financing secured into 2026 to drive NEX-22 development

2025-01-24 11:00:00 Equity Research | GRANGEX AB: PEA confirms robust economics for Sydvaranger – mapping the road to financial close in H2’25

2025-01-20 08:00:00 Equity Research | PROLIGHT: SpinChip deal highlights the strategic importance and valuation potential of Prolight's solution

2024-12-03 13:30:00 Equity Research | PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies

2024-11-29 10:30:00 Equity Research | Nanexa AB: Phase I results position NEX-22 for licensing opportunities and a head start in long-acting GLP-1

2024-11-28 08:00:00 Equity Research | PROLIGHT: Advancing with strengthened financials towards clinical performance study in 2025

2024-11-08 08:00:00 Equity Research | Nanexa: Progress for rival at Novo illustrates the significant value potential in Nanexa

2024-11-04 08:00:00 Equity Research | CRUNCHFISH: Detailing the eight revenue opportunities ahead

2024-10-31 08:00:00 Equity Research | TALLINK: All about the Dividend

2024-10-11 09:00:00 CRUNCHFISH: Video | Vd Joachim Samuelsson om kommande emission och affärsmöjligheterna inom DC offline och CBDC

2024-09-23 08:00:00 Equity Research | CRUNCHFISH: Rights issue to stay the course on extended timeline

2024-09-09 08:00:00 Equity Research | GRANGEX: Emerging as Europe’s top DR concentrate developer

2024-08-30 09:00:00 Equity Research | MOTION DISPLAY: Strong gross margin driving another profitable quarter

2024-08-29 09:00:00 Equity Research | PROLIGHT: Pre-validation readout in Q4 sets stage for multicenter trial in 2025

2024-08-28 08:00:00 Nanexa AB: NEX-22 Progress, Revaluation and Financing

2024-08-26 08:00:00 Equity Research | CRUNCHFISH: Three avenues to address the strained financing

2024-08-19 11:00:00 Equity Research | Agtira AB: Big launch and a capital-light expansion in the cards

2024-06-17 12:00:00 Equity Research | GRANGEX: Updated DFS confirming viability to produce high-grade iron ore at Dannemora

2024-06-04 08:00:00 Equity Research | Free2Move Holding AB: Another step up the PropTech value chain

2024-05-20 10:30:00 Equity Research | Prolight Diagnostics: SEK 17m UK grant a welcome external validation

2024-05-16 08:00:00 Equity Research | FREE2MOVE: Slow start to 2025 but with a sharp uptick in early Q2

2024-05-15 10:00:00 Equity Research | Agtira: Mixed start to pivotal 2024

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode